Skip to main content

Peer Review reports

From: Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Original Submission
26 Nov 2021 Submitted Original manuscript
25 Jun 2022 Reviewed Reviewer Report - Riaz Qureshi
20 Jul 2022 Reviewed Reviewer Report - Jan Rekowski
1 Feb 2023 Author responded Author comments - Sonia Jaramillo
Resubmission - Version 2
1 Feb 2023 Submitted Manuscript version 2
9 Feb 2023 Reviewed Reviewer Report - Riaz Qureshi
13 Feb 2023 Reviewed Reviewer Report - Jan Rekowski
4 Apr 2023 Reviewed Reviewer Report - Jay Herson
4 Apr 2023 Reviewed Reviewer Report - Hugh Jarrett
7 Apr 2023 Reviewed Reviewer Report - Ulviye Özcan Yüce
8 Apr 2023 Reviewed Reviewer Report - Laura Finneran
10 May 2023 Author responded Author comments - Sonia Jaramillo
Resubmission - Version 3
10 May 2023 Submitted Manuscript version 3
12 May 2023 Reviewed Reviewer Report - Hugh Jarrett
13 May 2023 Reviewed Reviewer Report - Jay Herson
14 May 2023 Reviewed Reviewer Report - Ulviye Özcan Yüce
26 May 2023 Reviewed Reviewer Report - Riaz Qureshi
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
27 May 2023 Editorially accepted
15 Sep 2023 Article published 10.1186/s13063-023-07421-x

You can find further information about peer review here.

Back to article page